Found: 6
Select item for more details and to access through your institution.
Empowering SARS‐CoV‐2 variant neutralization with a bifunctional antibody engineered with tandem heptad repeat 2 peptides.
- Published in:
- Journal of Medical Virology, 2024, v. 96, n. 3, p. 1, doi. 10.1002/jmv.29506
- By:
- Publication type:
- Article
Antibody-Based Targeting of Cell Surface GRP94 Specifically Inhibits Cetuximab-Resistant Colorectal Cancer Growth.
- Published in:
- Biomolecules (2218-273X), 2019, v. 9, n. 11, p. 681, doi. 10.3390/biom9110681
- By:
- Publication type:
- Article
A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1271508
- By:
- Publication type:
- Article
Development and Characterization of Phage-Display-Derived Novel Human Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2.
- Published in:
- Biomedicines, 2022, v. 10, n. 12, p. 3274, doi. 10.3390/biomedicines10123274
- By:
- Publication type:
- Article
Correction: Kim et al. Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. Cells 2021, 10 , 670.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 3, p. 670, doi. 10.3390/cells10030670
- By:
- Publication type:
- Article